secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2025-02-04T23:59:59+00:00
Accession:  0001804220-25-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q4 revenue up 10% to $3.79B; initiates $0.88 quarterly dividend, adds $3B buyback
--------------------------------------------------------------------------------

- Q4 GAAP diluted EPS $8.06 (-21% YoY); non-GAAP diluted EPS $12.07 (+2% YoY). Full year revenue $14.20B (+8%).
- Q4 Dupixent global net sales $3.70B (+15%); EYLEA HD/EYLEA US net sales $1.50B (+2%); Libtayo global $367M (+50%).
- Initiated quarterly cash dividend of $0.88/share, payable March 20, 2025. Board authorized additional $3.0B share repurchase (total capacity ~$4.5B).
- Regulatory applications submitted for EYLEA HD pre-filled syringe, Dupixent in bullous pemphigoid, linvoseltamab, and odronextamab.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/0001804220-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000180422025000007/regn-20250204.htm
  HTML page:      https://secwatch.observer/filing/0001804220-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer